Masimo Corporation

NASDAQ:MASI

Medical - Devices

Healthcare
$179.95 +0.00%

+$0.00 today

Market cap
$9.42B
Beta
1.10
P/E (TTM)
123.1
EPS (TTM)
$1.46
52W Low $125.94High $179.99

Volume 0.00M

Average 1.08M

MASI Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Masimo CorporationNASDAQ: MASI

Gross Margin · Q1 FY2026 · quarter ended Apr 2026

Gross margin narrows to 62.1%

Gross margin was 62.1% in Q1 FY2026, down 0.8 pp from a year earlier. On a trailing-twelve-month basis it was 61.7%, up 9.6 pp year over year. Over 3 fiscal years it widened by 9.9 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterApr 2026
62.1%+2.2 pp QoQ
Last fiscal yearJan 2026
61.9%+13.9 pp YoY
LTMApr 2026
61.7%+9.6 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-0.8 pp——
1 year+13.9 pp——
3 years+9.9 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
61.9%
Year-over-year change
+13.9pp

Gross Margin vs competitors

How MASI compares with its peers on the latest reported figures

  • MASI's LTM Apr 2026 gross margin of 61.7% is the 2nd highest of the 10 companies compared; the peer median is 30.3%.
  • Its year-over-year change of +9.6 pp is the highest of 10, against a peer median of -1.2 pp.
  • Over three fiscal years its change of +9.9 pp compares with a peer median of -3.5 pp.
MASI Competitors Peer median
Gross Margin for MASI and competitors
Company Period LTM level YoY 3-year change
RYTMRhythm Pharmaceuticals, Inc.LTM Sep 202688.2% -1.2 pp-1.2 pp
MASIMasimo CorporationLTM Apr 202661.7% +9.6 pp+9.9 pp
BIOBio-Rad Laboratories, Inc.LTM Jun 202651.9% -0.9 pp-3.9 pp
RGENRepligen CorporationLTM Jun 202651.1% +6.8 pp-9.8 pp
AVTRAvantor, Inc.LTM Jun 202631.8% -1.4 pp-2.0 pp
HSICHenry Schein, Inc.LTM Jun 202630.3% +1.0 pp+0.3 pp
BAXBaxter International Inc.LTM Jun 202630.1% -5.2 pp-5.2 pp
STVNStevanato Group S.p.A.LTM Jun 202629.2% +1.1 pp-3.5 pp
ATRAptarGroup, Inc.LTM Jun 202628.3% -6.3 pp-5.4 pp
MOHMolina Healthcare, Inc.LTM Sep 20268.1% -2.0 pp-3.3 pp
ABVXAbivax S.A.FY2025— ——
Peer median (excluding MASI) 30.3%-1.2 pp-3.5 pp

Competitors are the stored peer set for MASI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Jan 2026
Revenue1.24B2.04B2.05B2.09B1.53B
Cost of Revenue430.8M977M1.04B1.09B581.7M
Gross Profit808.4M1.06B1B1B945.2M
Gross Margin65.2%52.0%49.0%48.0%61.9%
Research & Development137.2M191.4M175.2M222.8M126.4M
Selling, General & Admin395.4M657.4M664M743.8M506M
Operating Expenses532.6M848.8M867M1.27B632.4M
Depreciation & Amortization35.6M136.1M98.3M103M38.8M
EBITDA310.3M355.2M236.7M(158.7M)344.6M
EBITDA Margin25.0%17.4%11.6%-7.6%22.6%
Operating Income275.8M210M136.5M(266.7M)312.8M
Operating Margin22.3%10.3%6.7%-12.7%20.5%
Interest Income900K1.8M3M4.8M3.4M
Interest Expense300K25.7M50.3M43.6M33.2M
Other Income / Expenses(1.4M)(16.6M)(48.4M)(38.6M)(40.2M)
Income Before Tax274.4M193.4M88.1M(305.3M)272.6M
Pre-Tax Margin22.1%9.5%4.3%-14.6%17.9%
Income Tax Expense44.8M49.9M6.6M(400K)64.9M
Net Income229.6M143.5M81.5M(304.9M)(151.5M)
Net Margin18.5%7.0%4.0%-14.6%-9.9%
EPS (Basic)4.162.681.54(5.72)(2.83)
EPS (Diluted)3.982.601.51(5.72)(2.80)
Weighted Avg Shares55.17M53.6M52.8M53.3M53.6M
Weighted Avg Shares (Diluted)57.68M55.2M54.1M53.3M54.2M

Masimo Corporation

NASDAQ:MASI

Intrinsic Alpha fair value

Locked

Current Price

$179.95

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.